title: Individual bioequivalence revisited.
abstract: For decades, the establishment of bioequivalence has generally relied on the comparison of population averages between the test and reference formulations. In the early 1990s, individual bioequivalence was proposed to ensure that an individual could be switched from the reference product to the test product with unchanged efficacy and safety. Since 1997, the US Food and Drug Administration (FDA) has published three guidance documents on the proposed criterion and statistical methodology for the individual bioequivalence approach. From a scientific stand-point, the individual bioequivalence criterion appears to offer several advantages for some drug products compared with the average criterion. It allows comparison of intraindividual variances, scaling the bioequivalence criterion to the reference variability and detection of an important subject-by-formulation interaction if it exists. Based on these considerations, the FDA has recently recommended replicate study designs for modified release dosage forms and highly variable drug products. The new criterion also promotes inclusion of a heterogeneous population of volunteers in bioequivalence studies. Despite all the advantages of the individual bioequivalence approach, questions remain on the optimal use of replicate study designs and the proposed criterion for evaluation of bioequivalence between formulations. In the finalised guidance documents, therefore, the FDA maintains the average bioequivalence criterion while allowing other criteria under certain circumstances. Collection and analysis of bioequivalence data from replicate study designs may permit further assessment and resolution of these questions.
authors.affiliation: Office of Pharmaceutical Science, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20857, USA.
authors.forename: M L
authors.initials: ML
authors.lastname: Chen
authors.forename: L J
authors.initials: LJ
authors.lastname: Lesko
mesh_terms: D001682:Biological Availability; D002626:Chemistry, Pharmaceutical; D005260:Female; D006801:Humans; D008297:Male; D012107:Research Design; D013810:Therapeutic Equivalency; D014481:United States; D014486:United States Food and Drug Administration